ClinicalTrials.gg
Not yet recruitingNCT06045195Pembro-FLASHUpdated Apr 6, 2025

Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma

A Phase 2 interventional study of Pembrolizumab in Hodgkin Lymphoma, sponsored by University of Cologne. Not yet recruiting at 1 site in Germany. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-04-06.

Sponsored by University of Cologne · Phase 2, Interventional, and Treatment

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies testing pembrolizumab in Hodgkin Disease — 12 open to participants now, 20 under way, 2 of them phase 3. pembrolizumab · Hodgkin Disease.

Planned enrollment
14th of 30
40 · median 34
Started
2025
with 1 other
Phase 2
22 of 30
10 open now
Primary completion
2027-01
later than 10 of 19 live
Registered
22nd of 30
by date
Lead sponsor
3 of 30
University of Cologne

Among the 30 studies testing pembrolizumab in Hodgkin Disease, this one is the 14th largest by planned enrollment, is one of 2 that started in 2025, is one of 22 in phase 2, reaches primary completion later than 10 of the 19 other live ones, and was the 22nd registered.

Hodgkin Disease

1,384 studies on the registry are indexed under Hodgkin Disease; 160 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

12 of the 30 studies testing pembrolizumab in Hodgkin Disease are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Hodgkin Disease studies recruiting now, 70 (53%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing pembrolizumab in Hodgkin Disease, or all of them as a file.
02

Study summary

The primary objective of this trial is to estimate efficacy of the novel regimen. The primary endpoint is the 1-year PFS rate after treatment with one dose of pembrolizumab followed by four to six cycles of chemo-immunotherapy with P-BrECADD, and PET-guided radiotherapy as per standard of care

03

Conditions studied

  • Hodgkin Lymphoma

Browse trials for

Keywords

  • advanced stage
  • first line treatment
  • PD-1 inhibitor
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • age 18-60
  • advanced stage classical Hodgkin Lymphoma
  • no previous treatment for cHL

Main Exclusion Criteria:

  • Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma
  • Chemotherapy or radiotherapy in medical history
  • Prior or concurrent disease that prevents treatment according to protocol
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Treatment

    Pembrolizumab + BrECADD

    Drug: Pembrolizumab

Interventions

  • As induction therapy, all participants will receive one dose of single-agent pembrolizumab (P) followed by two cycles of chemo-immunotherapy consisting of pembrolizumab and BrECADD (P-BrECADD). Response to induction therapy will be measured after 1x P (PET-1) and after 1x P + 2x P-BrECADD (PET-3). Further systemic treatment is PET-3-guided. Complete metabolic responses will be consolidated with two further cycles of P-BrECADD while participants with a positive PET-3 will receive four further cycles of P-BrECADD. PET-positive lesions after completion of chemo-immunotherapy will be recommended for consolidating radiotherapy according to standard of care.

06

What researchers measure

Primary outcomes

  1. progression free survival

    Time frame: 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Jan 2027, 17 months later.

Of 180 non-industry phase 2 interventional studies under Hodgkin Disease, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 115. This study's planned 17 months is below that.

Counting every sponsor, half of 203 studies reached it within 75 months; a quarter within 42 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2023
First posted
Sep 21, 2023
StartEst.
Aug 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2029
Last update
Apr 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06045195
Responsible party
Prof. Dr. Peter Borchmann (Prof., University of Cologne) — Principal investigator
First posted
Sep 21, 2023
Start date
Aug 2025 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Jan 2029 (estimated)
Last update
Apr 6, 2025

Study contacts

Michael Fuchs
Contact
michael.fuchs@uk-koeln.de
+49221478 ext. 88160
Peter Borchmann, Prof.
principal investigator · 1st Department of Medicine, Cologne University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion